Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR444245 plus other anticancer therapies in gastrointestinal cancers
CTR20220689Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Mar 2022
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pegenzileukin in Esophageal Squamous Cell Carcinoma (ESCC), gastric cancer (GC), gastroesophageal junction adenocarcinoma and 2 more (4 cohorts), sponsored by Sanofi. Primary endpoint: Objective response rate (ORR). Started Mar 2022; status: terminated.
02
Drugs
pegenzileukin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)gastric cancer (GC)gastroesophageal junction adenocarcinomahepatocellular carcinoma (HCC)colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20220689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220689.